The later-line efficacy and safety of immune checkpoint inhibitors plus anlotinib in EGFR-mutant patients with EGFR-TKI-resistant NSCLC: a single-center retrospective study
Article in Cancer Immunology, Immunotherapy (May 2024)
The most recent citing publications are shown below. View all 13 publications that cite this research output on Dimensions.
Article in Cancer Immunology, Immunotherapy (May 2024)
Article in BMC Pulmonary Medicine (February 2024)
Article in Cancers (November 2023)